Beidseitige Nivolumab-assoziierte Vogt-Koyanagi-Harada-artige Uveitis bei einem Patienten mit metastasiertem Nierenzellkarzinom

Czichos, Carolina; Wawrzynów, Bartlomiej; Chamalis, C; Jagow, Burkhard von

doi:10.1055/a-1306-0854

Cited by 2 publications

(2 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Genetic phenotype and viral infection are involved in the pathogenesis of the disease [7], and several cases of VKH disease-like uveitis after the initiation of ICI, which is often used in cancer treatment in recent years, have been reported. There are 15 cases of nivolumab-induced VKH disease-like uveitis, including ours [8][9][10][11][12][13][14][15][16][17][18][19][20] (Tables 1 and 2). Ophthalmic irAE are diverse, and the most common of which is uveitis (15.1%) [2].…”

Section: Discussionmentioning

confidence: 99%

Outcome of Nivolumab-Induced Vogt–Koyanagi–Harada Disease-Like Uveitis in a Patient Managed without Intravenous Methylprednisolone Therapy

Nagai

Yamamoto

Yoshida

et al. 2023

Case Reports in Ophthalmological Medicine

View full text Add to dashboard Cite

Background. In recent years, immune checkpoint inhibitors (ICI) have been often used for several types of cancers. Immune-related adverse events (irAEs) are autoimmune responses caused by ICI. Among the different types of irAEs, uveitis is common in ophthalmology. Moreover, there are reports on Vogt–Koyanagi–Harada (VKH) disease-like uveitis. In most cases, VKH, as in the usual VKH, is managed with intravenous methylprednisolone therapy. Case Report. A 72-year-old man was diagnosed with gastric cancer, and he was treated with nivolumab, a type of ICI. After eight cycles of nivolumab therapy, he developed fulminant type 1 diabetes mellitus and diabetic ketoacidosis. Thus, the treatment was discontinued. Subsequently, the patient was referred to our department due to bilateral blurry vision. He had decreased visual acuity in both eyes, and slit lamp examination revealed the presence of bilateral anterior chamber cells and keratic precipitates. Fundus examination showed bilateral serous retinal detachment (SRD), wavy retinal pigment epithelium (RPE), and choroidal thickening. Cerebrospinal fluid examination revealed prominent pleocytosis. Thus, we initiated eye drop therapy and subtenon injection of triamcinolone acetonide on the right eye only. After 1 month, SRD and wavy RPE disappeared, and the patient’s visual acuity improved. Further, both eyes had similar improvements in visual acuity and abnormal findings. Oral prednisolone was subsequently administered for hearing loss. However, intravenous methylprednisolone was not used, and ophthalmologic findings and visual acuity did not change before and after systemic steroid therapy. One year after disease onset, SRD and wavy RPE did not relapse. Conclusion. Nivolumab-induced VKH disease-like uveitis can have good outcomes even in a patient managed without intravenous methylprednisolone therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Outcome of Nivolumab-Induced Vogt–Koyanagi–Harada Disease-Like Uveitis in a Patient Managed without Intravenous Methylprednisolone Therapy

Nagai

Yamamoto

Yoshida

et al. 2023

Case Reports in Ophthalmological Medicine

View full text Add to dashboard Cite

show abstract

“…A study of individual case safety reports from the WHO international pharmacovigilance database found that ICIs and protein kinase inhibitors were the only drugs associated with druginduced VKH-like uveitis [68]. Our literature search yielded 24 retrospective studies, case reports, and case series analyzing VKH-like uveitis in the context of ICI therapy, totalling 41 patients [68][69][70][100][101][102][103][134][135][136][137][138][139][140][141][142][143][144][145][146][147][148][149][150]. Details of the included study data are found in Appendix B (Table A4).…”

Section: Vogt-koyanagi-harada-like Uveitismentioning

confidence: 99%

Diagnosing and Managing Uveitis Associated with Immune Checkpoint Inhibitors: A Review

Zhang,

Houadj,

et al. 2024

Diagnostics

View full text Add to dashboard Cite

This review aims to provide an understanding of the diagnostic and therapeutic challenges of uveitis associated with immune checkpoint inhibitors (ICI). In the wake of these molecules being increasingly employed as a treatment against different cancers, cases of uveitis post-ICI therapy have also been increasingly reported in the literature, warranting an extensive exploration of the clinical presentations, risk factors, and pathophysiological mechanisms of ICI-induced uveitis. This review further provides an understanding of the association between ICIs and uveitis, and assesses the efficacy of current diagnostic tools, underscoring the need for advanced techniques to enable early detection and accurate assessment. Further, it investigates the therapeutic strategies for ICI-related uveitis, weighing the benefits and limitations of existing treatment regimens, and discussing current challenges and emerging therapies in the context of their potential efficacy and side effects. Through an overview of the short-term and long-term outcomes, this article suggests recommendations and emphasizes the importance of multidisciplinary collaboration between ophthalmologists and oncologists. Finally, the review highlights promising avenues for future research and development in the field, potentially informing transformative approaches in the ocular assessment of patients under immunotherapy and the management of uveitis following ICI therapy.

show abstract

Beidseitige Nivolumab-assoziierte Vogt-Koyanagi-Harada-artige Uveitis bei einem Patienten mit metastasiertem Nierenzellkarzinom

Cited by 2 publications

References 9 publications

Outcome of Nivolumab-Induced Vogt–Koyanagi–Harada Disease-Like Uveitis in a Patient Managed without Intravenous Methylprednisolone Therapy

Outcome of Nivolumab-Induced Vogt–Koyanagi–Harada Disease-Like Uveitis in a Patient Managed without Intravenous Methylprednisolone Therapy

Diagnosing and Managing Uveitis Associated with Immune Checkpoint Inhibitors: A Review

Contact Info

Product

Resources

About